Background: Herpes zoster (HZ) is associated with underlying immunodeficiency and may thereby predict mortality of subsequent cancer.
Herpes zoster (HZ) may be a marker of occult cancer (Sørensen et al., 2004; Ho et al., 2011; Liu et al., 2012; Wang et al., 2012; Chiu et al., 2013; Cotton et al., 2013; Iglar et al., 2013) and some authors have advocated increased work-up for cancer in patients with HZ (Zaha et al., 1993; Yamamoto et al., 2003; Cotton et al., 2013) . However, limited data are available on whether HZ may be used to predict mortality in patients presenting with subsequent cancer in clinical practice. The two previous studies on the topic overall showed no association (Sørensen et al., 2004; Cotton et al., 2013) , but were limited by small sample sizes and lacked information on key prognostic factors, such as cancer stage and comorbidities. The first study, which was conducted by our research group, was furthermore restricted to in-patient HZ diagnoses (Sørensen et al., 2004) .
Our objective was to provide updated and more detailed analyses of the association between HZ and mortality following a subsequent cancer by extending the period of follow-up, by including inpatient, outpatient and emergency room HZ diagnoses, and by obtaining information on cancer stage, comorbidities and use of immunosuppressive drugs.
MATERIALS AND METHODS
We conducted this nationwide matched cohort study by using Danish nationwide medical databases. The source population comprised 829 787 cancer patients. A detailed description of data sources and variable definitions is provided in the Supplementary  Table S1 .
We identified all patients with a diagnosis of first-time cancer in the Danish Cancer Registry (Statens Serum Institut, 2012) between 1982 and 2011, who had a prior hospital-based (i.e., inpatient, outpatient (ambulatory), or emergency room) HZ diagnosis recorded in the Danish National Patient Registry (DNPR) (Lynge et al., 2011) . We considered all available primary and secondary registry diagnoses and used the date of discharge or end of outpatient follow-up as the diagnosis date for HZ. By grouping the diagnosis codes, we differentiated between severity (uncomplicated or complicated) and extent (localised or disseminated) of HZ. For each HZ patient with subsequent cancer, we sampled up to 10 cancer patients with no prior HZ diagnosis individually matched by sex, birth year, cancer type and calendar period of cancer diagnosis (5-year interval).
From the Danish National Health Service Prescription Database (Johannesdottir et al., 2012) and the DNPR, we retrieved information on the following covariates recorded before cancer diagnosis: treatment with immunosuppressive drugs within the first 6 months, comorbidities associated with immune dysregulation and comorbidity level categorised as none (0), moderate (1), severe (2) or very severe (X3) using the Charlson Comorbidity Index score (Charlson et al., 1987) .
By using the Civil Registration System (Schmidt et al., 2014) , we followed patients from the date of cancer diagnosis until death, emigration, or 31 December 2012, whichever came first. We computed the mortality rate per 1000 person-years for cancer patients with prior HZ and for the matched cancer cohort. Taking the matching variables into account, we used stratified Cox regression (Hosmer et al., 2008) to compute unadjusted mortality rate ratios (MRRs) with 95% confidence intervals (CIs) associating prior HZ with mortality following subsequent cancer. Then, we adjusted for comorbidity level and cancer stage (localised, regional, distant or unknown/missing). Because plots of the log(-log(survival)) vs log of survival time indicated non-proportionality, we divided follow-up time into 0-1 year and 41 year. We performed analyses for all cancers combined, cancer subgroups (haematological cancers, immune-related cancers, smoking-and alcoholrelated cancers and cancers at all other sites), and individual cancers (Boyle, 1997; Nasca, 2001; Boffetta and Hashibe, 2006) . Finally, we examined if the association depended on the included covariates through stratified analyses. As this analysis required dissolving of the matching, we used conventional Cox regression with additional adjustments for matching variables, cancer stage and comorbidity level in each subgroup analysis. All analyses were pre-specified.
RESULTS
We identified 2795 cancer patients with a prior HZ diagnosis and 26 243 cancer comparison cohort members without this diagnosis. Of these, 41 (1.5%) cancer patients with prior HZ were excluded because no matching cancer patients could be identified.
Cancer patients with prior HZ had a median age of 78 years and 56.9% were women (Table 1) . Compared with the matched cancer cohort, HZ patients had a higher prevalence of comorbidities and were more frequently users of immunosuppressive drugs before cancer diagnosis. Cancer stage at time of diagnosis was similar. The observed differences remained when cancer subtypes were examined separately (Supplementary Table S2 ).
The unadjusted MRR within the first year after cancer diagnosis was 0.95 (95% CI: 0.89-1.02), but decreased to 0.87 (95% CI: 0.81-0.93) in the full model, which was mainly explained by adjustment for comorbidity level (Table 2) . However, the stratified analysis (Table 3) . Again, an increased mortality rate was observed primarily for patients under the age of 60 years (aMRR 1.39; 95% CI: 1.07-1.79) and those with disseminated HZ (aMRR 1.21; 95% CI: 0.97-1.51) (Table 3 ). Thus, the youngest patients and patients with prior disseminated HZ had an increased mortality throughout the entire follow-up period (aMRRs 1.39; 95% CI: 1.15-1.68 and 1.18; 95% CI: 1.01-1.37, respectively). The increased estimates were particularly high among the patients with haematological or immune-related cancers (Supplementary  Tables S3-S6 ). The MRRs for individual cancers were imprecise but supported the findings from the main analyses (Supplementary  Table S7 ).
Finally, we observed no substantial difference or specific patterns when stratifying by time between HZ and cancer diagnoses (Table 3 and Supplementary Tables S3-S6 ).
DISCUSSION
We found that a hospital-based HZ diagnosis predicted an increased mortality in subsequent haematological and immunerelated cancers, particularly among patients aged o60 years and among those who had experienced disseminated HZ. For the remaining cancer patients, a prior HZ diagnosis was associated with a slightly decreased 1-year mortality.
In an earlier study, we found no overall association between HZ and mortality of subsequent cancer except for a potentially increased the mortality (MRR 1.38; 95% CI: 0.83-2.28) among patients with haematological malignancies diagnosed within a year after HZ (Sørensen et al., 2004) . In a British study, median survival was 1197 days among 573 cancer patients (87% of those identified) with prior HZ diagnosed in general practice compared with 1201 days among matched cancer patients without HZ (Cotton et al., 2013) . Our data suggest that prior studies may have been confounded by unmeasured comorbidity level. Also, our study allowed us to perform detailed subgroup analyses that revealed potentially important associations.
An intact immune system is essential both for withstanding carcinogenesis (Ershler, 1993; Penn, 2000) and varicella-zoster virus reactivation (Wilson, 2011) . HZ could therefore serve as a marker of underlying immune incompetence, possibly explaining the increased mortality of subsequent cancer. However, our results support this hypothesis in only a subgroup of patients. It is possible that disseminated infection and recrudescence in younger patients is a stronger marker of underlying immune incompetence. Indeed, disseminated HZ occurs more frequently in immunosuppressed individuals and HZ may be a presenting symptom of human immunodeficiency virus infection (Wilson, 2011; Søgaard et al., 2012) . Also, our estimates were driven by haematological and immune-related cancers, which are observed more frequently among immunosuppressed patients (Penn, 2000) . Because viruses have been implicated in the development of several of these cancers (Penn, 2000; Alibek et al., 2014) , we speculate whether the mechanisms behind immunological evasion of oncogenic viruses and the varicella-zoster virus are closely related. The slightly decreased mortality observed during the first year of follow-up is difficult to reconcile with our a priori hypothesis. Similar stage distribution argues against increased cancer surveillance among HZ patients as an explanation.
Strength of our study is the nationwide setting in a uniform healthcare system with complete follow-up data (Schmidt et al., 2014) . Also, the Danish Cancer Registry has high completeness, maintained by notifications from multiple sources of the healthcare system. High validity (i.e., positive predictive value) is supported by a high proportion of histologically verified tumours (over 90% for major cancers) and a low proportion (0.1%) of diagnoses based on death certificates only (Statens Serum Institut, 2012) .
We believe that the clinical picture of HZ confers a high diagnostic accuracy (Wilson, 2011) and thus positive predictive value in the DNPR. However, it is possible that physicians underreport HZ in elderly hospital patients, because they often have other diseases requiring greater clinical attention. Such misclassification could explain the lack of an association among patients aged X60 years. Unmeasured confounding by lifestyle factors, for example, smoking, could also explain the unexpected results if HZ is underreported in patients with lifestyle-related comorbidities or if cancer patients with previous HZ represent healthier persons as they have survived competing diseases after their HZ diagnosis in order to be diagnosed with cancer and thus included in our study. We also lacked data on cancer treatment, but because major determinants of treatment choice (i.e., age, stage and comorbidity) were included, we do not believe that it had major impact on our results. However, residual confounding because of missing information on stage is possible, in particular for haematological cancers. Nevertheless, inclusion of this variable in the model did not suggest that it was a major confounder.
Because the observed association depended on HZ severity, our findings may not be applicable to mild HZ treated in general practice. Furthermore, members of the comparison cohort may have had HZ treated in general practice, possibly resulting in bias towards the null. Misclassification in subgroups of severity and extent of HZ is another limitation as some ICD-8 codes are unspecific. Because we grouped such codes as uncomplicated and localised, it cannot explain the increased MRRs observed for disseminated HZ.
Finally, we performed several subgroup analyses, which may have resulted in some spurious findings. However, the particularly increased MRRs found for the youngest age group and disseminated HZ were consistent for both haematological and immunerelated cancers.
In conclusion, hospital-based HZ did not predict increased mortality of subsequent cancer except in patients with haematological or immune-related cancer, particularly among patients aged o60 years and those with disseminated infection. 
